Horizon Therapeutics Public Limited Company (HZNP)

108.52 +0.72 (+0.67%) At close: 04:00PM EDT

Horizon Therapeutics Public Limited Company

70 St. Stephen’s Green
Dublin 2
Ireland
353 1 772 2100
https://www.horizontherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 2,095

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Timothy P. Walbert	Chairman, Pres & CEO	5.54M	2.79M	1967
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.	Exec. VP & Chief Medical Officer	1.65M	5.89M	1955
Mr. Paul W. Hoelscher	Advisor	2.07M	806.39k	1965
Mr. Andy Pasternak	Exec. VP & Chief Strategy Officer	1.67M	3.74M	1971
Mr. Aaron L. Cox	Exec. VP of Fin. & CFO	N/A	N/A	1983
Mr. Patrick McIlvenny	Sr. VP & Chief Accounting Officer	N/A	N/A	1979
Ms. Tina E. Ventura	Sr. VP & Chief Investor Relations Officer	N/A	N/A	N/A
Mr. Sean M. Clayton J.D.	Exec. VP & Gen. Counsel	N/A	N/A	1979
Mr. Geoffrey M. Curtis	Exec. VP of Corp. Affairs & Chief Communications Officer	N/A	N/A	1975
Ms. Jane Gonnerman	Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Corporate Governance

Horizon Therapeutics Public Limited Company’s ISS Governance QualityScore as of February 1, 2023 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.